Proinflammatory cytokines (TNF alpha and IL-6) in Egyptian SLE patients with lupus nephritis

European Journal of General Medicine

Volumn 2, Issue 4, 2005, Pages 153-158

  Sabry, Alaa A ^a   Kalil, Abdalla M ^a   El Rahim, Mona Abd ^a   El Shahat, Fagr Bazyeed ^b   Elbasyouni, Sherief Refat ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

IL6; Lupus nephritis; SLE; TNF

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL EXAMINATION; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EGYPT; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 41449102428     PISSN: 13043889     EISSN: None     Source Type: Journal    
DOI: 10.29333/ejgm/82333     Document Type: Article

References (28)

1. Brink I, Thiele B, Burmester GR, Trebeljahr G, Emmrich F, Hiepe F. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-a in whole blood samples from patients with systemic lupus erythematosus. Lupus 1999;8:723-30
2. Lauwerys BR. Houssiau FA. Involvement of Cytokines in the Pathogenesis of Systemic Lupus Erythematosus. Adv Exp Med Biol 2003;520:237-51
3. Aringer M, Zimmermann C, Graninger WB et al. TNF-α is an essential mediator in lupus nephritis. Arthritis Rheum 2002;46:3418-9
4. Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8
5. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor-α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74
6. Al-Janadi M, al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993;13:58-67
7. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity. Clin Exp Immunol 1992;90:106-110
8. Linker Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1972;63:10-12
9. Lacki JK, Samborski W, Mackiewicz SH. Interleukin-10 and interleukin- 6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 1997;16:275-8
10. Tan EM, Cohen AS, Fries JI et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40
12. Aderka D, Engelman H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;75(2):323-9
13. Montero-Julian FA, Gautherot E, Wijdenes J, Klein B, Brailly H. Pharmacokinetics of interlukin-6 during therapy with anti-interlukin-6 monoclonal antibodies: enhanced clearance of interlukin-6 by a combination of three anti-interlukin-6 antibodies. J Interferon Res 1994;14(5):301-2
14. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol 2000;12:364-8
15. Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis. Semin Nephrol 1999;19:48-56
16. Jacobs C, Pawlak R, Mikeska E et al. Systemic lupus erythmatosus and rheumatoid arthritis differ from healthy controls in their cytokine pattern after stress exposure. Lupus 2001;40:868-75
17. Rieckmann P, Tuscano JM, Kehrl JH. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods 1997;11:128-32
18. Strand V. Monoclonal antibodies and other biologic therapies. Lupus 2001;10:216-21
19. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:146-50
20. Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 2005;38(2):134-41
21. Munk ME, Anding P, Schettini AP, Cunha MG, Kaufmann SH. Soluble tumor necrosis factor alpha receptors in sera from leprosy patients. Infect Immun 1999;67(1):423-5
22. Kelly JA, Moser KL, Harley JB: The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun 2002;3(Suppl):S71-S85
23. Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Semin Immunopathol 1994;16:181-200
24. Hiepe F, Volk HD, Apostolff E et al. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 1991;338: 1529-30
25. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995;26:558-64
26. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91
27. Hirohata S, Miyamoto, T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9
28. Raskovic S, Bogic M, Peric-Popadic A et al. Laporatory and morphologic parameters in patients with lupus nephritis. Spr Arh Celock Lek. 2002:130(3)38-41